July 31, 2012 (Investorideas.com Newswire) - eResearch Corp reports The first of Bioniche Life Sciences Inc.'s two canine oncology products has received approval from regulators in both Canada and the USA.
The Company has begun market launch activities, and the product - Immunocidin™ - is expected to be available in September 2012 in Canada. A U.S. launch is expected before the end of the year.
Immunocidin™ is based on Bioniche's proprietary cell wall technology, which is derived from the same platform as the Company's Phase III product for human bladder cancer. Immunocidin™ is indicated as an immunotherapy for the intra-tumoral treatment of canine mixed mammary tumour and mammary adenocarcinoma.
Canine cancer is the leading disease-related cause of death in dogs - about one in four dogs dies of cancer. Human chemotherapy is commonly used for treatment of canine cancer, but side effects can affect a dog's quality of life.
Bioniche's Second Canine Therapy
The Company is undertaking dose-confirmation studies for its second canine cancer therapy - an intravenous (I.V.) therapy - before conducting final licensing studies. This work is expected to be completed over the next six to nine months, and then regulatory approvals will be sought (first in North America, then in Australia and Europe).
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.